Neumora Therapeutics, Inc.2025财年第一财季实现净利润-67.99百万美元，同比减少26.56%

市场透视2025-05-19

5月19日，Neumora Therapeutics, Inc.（NMRA.US）公布财报，公告显示公司2025财年第一财季净利润为-67.99百万美元，同比减少26.56%；其中营业收入为0.00美元，每股基本收益为-0.42美元。从资产负债表来看，Neumora Therapeutics, Inc.（NMRA.US）总负债28.38百万美元，其中短期债务938000.00美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536059100?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536059100","market":"us","top_or_hot":-1,"title":"Neumora Therapeutics, Inc.2025财年第一财季实现净利润-67.99百万美元，同比减少26.56%","media":"市场透视","content":"<div>\n<p>5月19日，Neumora Therapeutics, Inc.（NMRA.US）公布财报，公告显示公司2025财年第一财季净利润为-67.99百万美元，同比减少26.56%；其中营业收入为0.00美元，每股基本收益为-0.42美元。从资产负债表来看，Neumora Therapeutics, Inc.（NMRA.US）总负债28.38百万美元，其中短期债务938000.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000138a482f002&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neumora Therapeutics, Inc.2025财年第一财季实现净利润-67.99百万美元，同比减少26.56%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeumora Therapeutics, Inc.2025财年第一财季实现净利润-67.99百万美元，同比减少26.56%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000138a482f002&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Neumora Therapeutics, Inc.（NMRA.US）公布财报，公告显示公司2025财年第一财季净利润为-67.99百万美元，同比减少26.56%；其中营业收入为0.00美元，每股基本收益为-0.42美元。从资产负债表来看，Neumora Therapeutics, Inc.（NMRA.US）总负债28.38百万美元，其中短期债务938000.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000138a482f002&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000138a482f002&s=b","article_id":"2536059100","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000138a482f002&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536059100","pubTimestamp":1747584035,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Neumora Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-67.99百万美元，同比减少26.56%；其中营业收入为0.00美元，每股基本收益为-0.42美元。机构评级：截至2025年5月19日，当前有6家机构对Neumora Therapeutics, Inc.目标价做出预测，其中目标均价为5.67美元，其中最低目标价为1.00美元，最高目标价为18.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","NMRA":"Neumora Therapeutics, Inc."},"translate_title":"Neumora Therapeutics, Inc. achieved net profits of-US $67.99 million in the first fiscal quarter of fiscal 2025, a year-on-year decrease of 26.56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"NMRA":1},"content_text":"5月19日，Neumora Therapeutics, Inc.（NMRA.US）公布财报，公告显示公司2025财年第一财季净利润为-67.99百万美元，同比减少26.56%；其中营业收入为0.00美元，每股基本收益为-0.42美元。从资产负债表来看，Neumora Therapeutics, Inc.（NMRA.US）总负债28.38百万美元，其中短期债务938000.00美元，资产负债比为0.10，流动比率为0.09。机构评级：截至2025年5月19日，当前有6家机构对Neumora Therapeutics, Inc.目标价做出预测，其中目标均价为5.67美元，其中最低目标价为1.00美元，最高目标价为18.00美元。公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，成立的初衷是通过采用一种全新的方法来开发脑部疾病治疗方案，以应对脑部疾病危机。该公司已扩大其治疗产品线，目前包括七个临床和临床前神经科学项目，旨在针对一系列未得到充分治疗的神经精神障碍和神经退行性疾病的新型作用机制。其产品包括 NMRA-140、NMRA-511、NMRA-266、NMRA-M4R、NMRA-NMDA、NMRA-CK1O、NMRA-NLRP3 和 NMRA-GCASE。该集团的产品线正在构建针对未得到充分治疗的神经精神障碍和神经退行性疾病的项目。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536059100","isCrawlerRequest":true}